Arun S. Menawat - 15 May 2025 Form 4 Insider Report for Profound Medical Corp. (PROF)

Role: CEO, Director
Signature: /s/ Arun Menawat
Issuer symbol: PROF
Transactions as of: 15 May 2025
Net transactions value: +$100,151
Form type: 4
Filing time: 20 May 2025, 13:56:42 UTC
Previous filing: 12 Mar 2025
Next filing: 20 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Menawat Arun Swarup	CEO, Director	C/O PROFOUND MEDICAL CORP., 2400 SKYMARK AVENUE, UNIT 6, MISSISSAUGA, ONTARIO, CANADA	/s/ Arun Menawat	20 May 2025	0001685893

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PROF	Common Shares	Purchase	$43,263	+10,003	+1.8%	$4.32	575,062	15 May 2025	Direct	F1
transaction	PROF	Common Shares	Purchase	$56,888	+12,027	+2.1%	$4.73	587,089	16 May 2025	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.35, inclusive. The reporting person undertakes to provide to Profound Medical Corp., any security holder of Profound Medical Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.70 to $4.78, inclusive. The reporting person undertakes to provide to Profound Medical Corp., any security holder of Profound Medical Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.35, inclusive. The reporting person undertakes to provide to Profound Medical Corp., any security holder of Profound Medical Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.70 to $4.78, inclusive. The reporting person undertakes to provide to Profound Medical Corp., any security holder of Profound Medical Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Remarks:

As a foreign private issuer, Profound Medical Corp. securities are currently exempt from Section 16 pursuant to Rule 3a12-3(b) of the Exchange Act. As such, this is an informational and voluntary report which shall not be deemed an admission that, as of the date hereof, the filing person is required to report changes in beneficial ownership of Profound Medical Corp. securities registered under Section 12 of the Exchange Act.